5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | BUY | BUY | BUY | BUY |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 0.81▼ | 0.81▲ | 0.81▲ | 0.79▲ | 0.77▲ |
MA10 | 0.81▲ | 0.80▲ | 0.80▲ | 0.80▼ | 0.74▲ |
MA20 | 0.80▲ | 0.81▲ | 0.81▲ | 0.76▲ | 0.77▲ |
MA50 | 0.81▼ | 0.80▲ | 0.79▲ | 0.73▲ | 0.86▼ |
MA100 | 0.77▲ | 0.76▲ | 0.75▲ | 0.77▲ | 1.00▼ |
MA200 | 0.72▲ | 0.74▲ | 0.75▲ | 0.86▼ | 1.16▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.002▲ | 0.000▲ | -0.001▼ | 0.002▲ | 0.015▲ |
RSI | 51.427▲ | 51.460▲ | 51.969▲ | 57.357▲ | 49.873▼ |
STOCH | 69.898 | 74.621 | 75.359 | 56.472 | 67.334 |
WILL %R | -20.408▲ | -15.152▲ | -34.118 | -34.717 | -23.098▲ |
CCI | 61.529 | 60.703 | 42.136 | 42.690 | 87.409 |
Thursday, March 28, 2024 02:30 PM
Govorestat is a central nervous system (CNS) penetrant Aldose Reductase Inhibitor (ARI) in development for the treatment of several rare neurological diseases, including Galactosemia, SORD Deficiency, ...
|
Thursday, March 28, 2024 10:08 AM
Nestled amidst rolling hills in Apopka, our master-planned resort-style community offers an idyllic setting for those seeking both charm ...
|
Thursday, March 28, 2024 07:33 AM
Q4 2023 Earnings Call March 27, 2024 Cellectar Biosciences, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
28/03/24 | 0.7837 | 0.8248 | 0.78 | 0.8021 | 67,754 |
27/03/24 | 0.76 | 0.815 | 0.76 | 0.801 | 109,228 |
26/03/24 | 0.7839 | 0.8106 | 0.76 | 0.76 | 54,569 |
25/03/24 | 0.8034 | 0.85 | 0.7203 | 0.76 | 276,997 |
22/03/24 | 0.80 | 0.8299 | 0.80 | 0.829 | 47,752 |
21/03/24 | 0.82 | 0.8355 | 0.815 | 0.815 | 73,948 |
20/03/24 | 0.85 | 0.8598 | 0.81 | 0.8101 | 160,497 |
19/03/24 | 0.8392 | 0.8448 | 0.81 | 0.8448 | 327,519 |
18/03/24 | 0.78 | 0.823 | 0.7614 | 0.823 | 163,082 |
15/03/24 | 0.77 | 0.79 | 0.7695 | 0.7878 | 47,362 |
|
|
||||
|
|
||||
|
|